Molecule intelOpportunity: StrongEssential

Mesalazine

13 brands · 10 companies · product forms

ATC: A07EC02

Opportunity snapshot

Launch attractiveness
50
Market saturation
26
Price room
100
Regulatory risk
0
13
brands
10
companies
Rs 889.9
median price
7
price points
10.5x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 15%

Price room

Across observed sources and strengths
CheapestRs 443.3
MedianRs 889.9
Most expensiveRs 4,654.11
Spread10.5×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 10.50x across 7 trusted points (Rs 443.3-4654.11). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 5 live products for Mesalazine — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(74) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

10 canonical companies and 13 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 10.50x across 7 trusted points (Rs 443.3-4654.11). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this strong opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.